The Zhitong Finance App learned that on July 24, the Securities Regulatory Commission issued the “Approval to Register the Initial Public Offering of Shares by Nantong Lianya Pharmaceutical Co., Ltd.” According to reports, Lianya Pharmaceutical is listed on the Shenzhen Stock Exchange, and CICC is the sponsor and plans to raise 950 million yuan.
According to the prospectus, Lianya Pharmaceutical is an R&D-driven high-tech enterprise, mainly engaged in R&D, production and sales of complex pharmaceutical preparations. Currently, its products mainly include two types of high-end generic drugs represented by different types of controlled-release formulations and low-dose pharmaceutical preparations. As of March 31, 2026, the company relied on 6 self-developed technology platforms to complete the development of various products. In overseas markets, 48 self-developed products have been approved by the US FDA, and 1 product has been approved in Canada. Indications include high blood pressure, coronary heart disease, diabetes, and female contraception.
According to the statistics of Insight Consulting, as of the end of the reporting period, the company ranked third in the country in terms of the total number of ANDA approved by the FDA, the number of oral controlled release formulations approved by the FDA ranked first in the country, the number of controlled standard formulations (RS) independently developed and certified by the FDA ranked first in the country, and several controlled release formulations ranked first in the US market share.